Prostate cancer (PCa) risk variants and risk of fatal PCa in the national cancer institute breast and prostate cancer cohort consortium

IM Shui; S Lindström; AS Kibel; SI Berndt; D Campa; T Gerke; KL Penney; D Albanes; C Berg; HB Bueno-De-Mesquita; S Chanock; ED Crawford; WR Diver; SM Gapstur; JM Gaziano; GG Giles; B Henderson; R Hoover; M Johansson; L Le Marchand; J Ma; C Navarro; K Overvad; FR Schumacher; G Severi; A Siddiq; M Stampfer; VL Stevens; RC Travis; D Trichopoulos; P Vineis; LA Mucci; M Yeager; E Giovannucci; P Kraft

Journal article

Prostate cancer (PCa) risk variants and risk of fatal PCa in the national cancer institute breast and prostate cancer cohort consortium

IM Shui, S Lindström, AS Kibel, SI Berndt, D Campa, T Gerke, KL Penney, D Albanes, C Berg, HB Bueno-De-Mesquita, S Chanock, ED Crawford, WR Diver, SM Gapstur, JM Gaziano, GG Giles, B Henderson, R Hoover, M Johansson, L Le Marchand Show all

European Urology | Published : 2014

DOI: 10.1016/j.eururo.2013.12.058

Abstract

Background Screening and diagnosis of prostate cancer (PCa) is hampered by an inability to predict who has the potential to develop fatal disease and who has indolent cancer. Studies have identified multiple genetic risk loci for PCa incidence, but it is unknown whether they could be used as biomarkers for PCa-specific mortality (PCSM). Objective To examine the association of 47 established PCa risk single-nucleotide polymorphisms (SNPs) with PCSM. Design, setting, and participants We included 10 487 men who had PCa and 11 024 controls, with a median follow-up of 8.3 yr, during which 1053 PCa deaths occurred. Outcome measurements and statistical analysis The main outcome was PCSM. The risk a..

View full abstract

University of Melbourne Researchers

Graham Giles Author

Grants

Awarded by National Institutes of Health

Funding Acknowledgements

This work was supported by the NIH NCI (cooperative agreement U19 CA148537-01). The maintenance of the Cancer Prevention Study II is supported by the American Cancer Society, and genotyping of the CPS-II samples was supported by a grant from the NCI (5U01CA098710). The Danish study Diet, Cancer and Health was funded by the Danish Cancer Society. EPIC-Greece was supported through the Hellenic Health Foundation. EPIC-Spain was supported by Health Research Fund; the regional governments of Andalucia, Asturias, Basque Country, Murcia (No. 6236), and Navarra; and ISCIII RETIC (RD06/0020; Spain). PLCO was supported by the intramural program of the Division of Cancer Epidemiology and Genetics, NCI. The Melbourne Collaborative Cohort Study recruitment was funded and its follow-up supported by Cancer Council Victoria.